CN116724028B - 抗肿瘤的抗坏血酸酯 - Google Patents

抗肿瘤的抗坏血酸酯 Download PDF

Info

Publication number
CN116724028B
CN116724028B CN202180062720.9A CN202180062720A CN116724028B CN 116724028 B CN116724028 B CN 116724028B CN 202180062720 A CN202180062720 A CN 202180062720A CN 116724028 B CN116724028 B CN 116724028B
Authority
CN
China
Prior art keywords
compound
esi
mmol
compounds
ethyl acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180062720.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116724028A (zh
Inventor
T·罗约巴格斯
Y·福尔迪奥普
M·G·D·L·Á·戈麦斯帕西奥斯
H·桑塔亚加西亚
F·加里多费尔南德斯
G·库茨
M·卢比艾斯罗约
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Unique Cosmetics Co
Original Assignee
Unique Cosmetics Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Unique Cosmetics Co filed Critical Unique Cosmetics Co
Publication of CN116724028A publication Critical patent/CN116724028A/zh
Application granted granted Critical
Publication of CN116724028B publication Critical patent/CN116724028B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/32—Oxygen atoms
    • C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180062720.9A 2020-09-14 2021-09-13 抗肿瘤的抗坏血酸酯 Active CN116724028B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20382804.1A EP3967684A1 (en) 2020-09-14 2020-09-14 Antitumoral ascorbic acid esters
EP20382804.1 2020-09-14
PCT/EP2021/075104 WO2022053679A1 (en) 2020-09-14 2021-09-13 Antitumoral ascorbic acid esters

Publications (2)

Publication Number Publication Date
CN116724028A CN116724028A (zh) 2023-09-08
CN116724028B true CN116724028B (zh) 2025-07-08

Family

ID=72709280

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180062720.9A Active CN116724028B (zh) 2020-09-14 2021-09-13 抗肿瘤的抗坏血酸酯

Country Status (10)

Country Link
US (1) US20230278974A1 (enExample)
EP (2) EP3967684A1 (enExample)
JP (1) JP7805651B2 (enExample)
KR (1) KR20230088718A (enExample)
CN (1) CN116724028B (enExample)
AU (1) AU2021339010A1 (enExample)
CA (1) CA3191119A1 (enExample)
ES (1) ES3006988T3 (enExample)
MX (1) MX2023002970A (enExample)
WO (1) WO2022053679A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024231868A1 (en) * 2023-03-09 2025-10-23 Mastery Biotech Co., Ltd. Conjugate compound comprising 13-cis-retinoic acid and ascorbic acid

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106139151A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物
WO2018026673A1 (en) * 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2831395B2 (ja) * 1989-09-12 1998-12-02 ハリマ化成株式会社 アスコルビン酸エステル
JP3781877B2 (ja) * 1997-10-03 2006-05-31 株式会社ムック アスコルビン酸誘導体またはその塩、および医薬
CN101550119B (zh) * 2009-05-11 2012-05-30 无锡宏瑞生物医药科技有限公司 芳基(乙)丙酸抗坏血酸酯,其制备方法及含有它们的药物
JP2016104708A (ja) 2014-12-01 2016-06-09 参天製薬株式会社 アスコルビン酸誘導体を含有する非水性注射剤及びデポ形成方法
JP6588764B2 (ja) 2015-01-26 2019-10-09 章博 田井 抗腫瘍剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106139151A (zh) * 2016-04-29 2016-11-23 陈西敬 抗坏血酸棕榈酰酯与抗肿瘤药物协同作用的药物组合物
WO2018026673A1 (en) * 2016-08-01 2018-02-08 IC-MedTech Corp. Ascorbic acid, quinone compound, and sodium glucose cotransporter inhibitor for treating cancer

Also Published As

Publication number Publication date
EP4211123B1 (en) 2024-11-06
MX2023002970A (es) 2023-05-15
EP4211123A1 (en) 2023-07-19
US20230278974A1 (en) 2023-09-07
EP4211123C0 (en) 2024-11-06
KR20230088718A (ko) 2023-06-20
EP3967684A1 (en) 2022-03-16
ES3006988T3 (en) 2025-03-19
JP7805651B2 (ja) 2026-01-26
CA3191119A1 (en) 2022-03-17
AU2021339010A1 (en) 2023-03-23
CN116724028A (zh) 2023-09-08
WO2022053679A1 (en) 2022-03-17
JP2023541840A (ja) 2023-10-04

Similar Documents

Publication Publication Date Title
EP3002285B1 (en) Tetrahydrocarboline derivative
US20140148400A1 (en) Carbonic anhydrase inhibitors with antimetastatic activity
EP3760626B1 (en) Novel compound and composition for preventing, ameliorating, or treating fibrosis or nonalcoholic steatohepatitis comprising same as active ingredient
KR102579485B1 (ko) 5-아자사이티딘류의 당 부분(糖部) 실릴에테르 유도체
WO2018133661A1 (zh) 一种新的硼酸衍生物及其药物组合物
CN102010421A (zh) 青蒿素类衍生物及其应用
EP4211123B1 (en) Antitumoral ascorbic acid esters
EP1773835B1 (fr) Derives de pyrido-pyrido-pyrimidine, leur preparation, leur application dans le traitement du cancer
EP1902054B1 (fr) Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique
US20140155334A1 (en) Polyphosphate and pyrophosphate derivative of saccharides
JP5701387B2 (ja) ベルバミンのジカルボキシミド誘導体、その調製方法及び使用
EP1911451A1 (en) Protein-kinase CK2 inhibitors and their therapeutic applications
CN113861214A (zh) 1,2,3-三唑栓系双氢青蒿素-靛红杂化物及其制备方法和应用
JP5034039B2 (ja) Ｇｍ３類似体
CN120289432B (zh) 一种具有极光激酶b和表皮生长因子受体双重抑制作用的喹啉类化合物及用途
US12152025B2 (en) Process for preparing alkynyl-containing compound and intermediate thereof
CN110183471B (zh) 一种哌嗪类衍生物及制备方法及应用
WO2005073211A1 (fr) Derives de pyranone utiles pour le traitement du cancer
KR20260035194A (ko) 미토콘드리아 특이적 전사 억제제 화합물
WO2022206350A1 (en) Metap-2 inhibitors, pharmaceutical compositions and therapeutic methods thereof
KR20260006834A (ko) 이미다졸리움계 화합물, 또는 이의 약학적으로 허용가능한 염 및 이를 포함하는 암 치료용 약학적 조성물
JP4324687B2 (ja) ２−（３−ニトロベンゾイル）安息香酸誘導体を有効成分とする医薬
WO2010090234A1 (ja) 12-デオキシフシコクシン糖鎖改変誘導体およびその用途
JP2016190796A (ja) 抗がん剤
JPS63216866A (ja) ６−アザプロスタサイクリン類似化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant